Floatz logo

Nivolumab

Renal Carcinoma

Fondazione Policlinico Universitario Agostino Gemelli IRCCSmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

41 Active assets in the Renal Carcinoma cohort.

Asset / SponsorPhaseRating
Cabozantinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Ipilimumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Lenvatinib
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3B
ROPIVACAINE
Wake Forest University Health Sciences
Phase 3B

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
metastatic melanomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
lung adenocarcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →